Avesthagen, a systems biology biotechnology company, has signed a memorandum of understanding with Kutlo-Nitt, a Niigata-based consortium of 11 Japanese universities and two technology licensing organisations.

According to Dr Villoo Morawala-Patell, Founder and CMD of Avesthagen, “Through this MoU, we will gain access to a suite of cutting-edge consortium technologies related to bio-pharmaceuticals and biomarkers for use in cancer and heart disease.”

“At later stage both Avesthagen and Kutlo-Nitt will jointly develop and commercialise the technologies,” she added.

The partnership is expected to bring important diagnostics and therapies to patients throughout the world. Avesthagen continues its commitment to deliver the best therapeutic and diagnostics solutions.

The consortium is represented by Mr Yoji Yuki, Senior Vice-President, Tech-Transfer Specialist, Kutlo-Nitt and Dr. Hiroko Sato, Technology Transfer Specialist.

Ms Villoo Patell said the company's convergence of food, pharma and population genetics leading to predictive preventive and personalised healthcare is progressing well.

“We have partners which include multiple global companies in each of its fields of research. Since its inception we have grown into a leading healthcare biotech companies. Avesthagen has developed clinically validated botanical bioactives and has a strong pipeline of bio-similars,” she added.

>anil.u@thehindu.co.in

Related Topics
comment COMMENT NOW